Anorexia and cancer in animals and man

Garattini, Silvio; Bizzi, A.; Donelli, M.G.; Guaitani, A.; Samanin, R.; Spreafico, F.

doi:10.1016/s0305-7372(80)80027-2

Cited by 44 publications

(14 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These still undetermined factors might be suramin insensitive. One such suramin-insensitive factor may be the competition between progressing C-26 tumors and the host for essential nutrients, a phenomenon known to occur in experimental cachexia (38). The beneficial effect of suramin on weight loss is not due to added nutritional value, since the drug is known to be poorly metabolized (22).…”

Section: Discussionmentioning

confidence: 99%

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Strassmann¹,

Fong²,

Freter³

et al. 1993

J. Clin. Invest.

118

View full text Add to dashboard Cite

Neoplastic diseases are frequently associated with metabolic changes collectively known as cancer cachexia. The presence of cachexia complicates therapeutic intervention and is an important cause of death in cancer patients. At present there is no effective treatment for cachexia. Recently, the involvement of interleukin-6 (IL-6) in the wasting of colon-26 adenocarcinoma-bearing mice was demonstrated. The research presented here establishes an anticachectic role for the experimental drug suramin, since it partially blocks (up to 60%) the catabolic effects associated with the growth of this tumor in vivo. Suramin prevents the binding of IL-6 to its cell surface receptor subunits, as demonstrated by radioreceptor binding assay and affinity crosslinking experiments. Furthermore, the uptake of radioactive IL-6 by the liver is significantly reduced in suramintreated mice. On the other hand, the drug is 10-fold less potent in inhibiting the binding of tumor necrosis factor-a to indicator cell line in vitro and fails to block liver uptake of this cytokine in vivo. Collectively, these results suggest that suramin inhibits cancer-associated wasting, in part by interfering with the binding of IL-6 to its receptor. Whether suramin inhibits the action ofother factors /cytokines that may also participate in colon-26-mediated cachexia is not yet known. (J. Clin.

show abstract

Section: Discussionmentioning

confidence: 99%

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Strassmann¹,

Fong²,

Freter³

et al. 1993

J. Clin. Invest.

118

View full text Add to dashboard Cite

show abstract

“…Instead cachexia is usually studied in rapidly growing rodent tumours, and appears as a late effect, usually just before death, when the tumour mass has reached a high proportion of the total weight of the animal. Usually these models attribute the cachexia to a drop in food intake and competition of the tumour with the host for essential nutrients (Garattini et al, 1980). The few models which do fulfill the criteria of an early effect and a small tumour mass, observe weight loss without a detectable loss of appetite (Strain et al, 1980;Bibby et al, 1987;Tanaka et al, 1990).…”

Section: Model Systems Of Cachexiamentioning

confidence: 99%

Cancer cachexia

Tisdale¹

1991

Br J Cancer

View full text Add to dashboard Cite

“…Walker 256 carcinosarcoma, a well-established model for the study of cachexia (9), was inoculated into Wistar rats, and the fat and protein content, the lipid composition and morphometric and ultrastructural aspects of the three fat depots were studied.…”

Section: Introductionmentioning

confidence: 99%

Heterogeneous response of adipose tissue to cancer cachexia

Bertevello

Seelaender

2001

Braz J Med Biol Res

View full text Add to dashboard Cite

Cancer cachexia causes disruption of lipid metabolism. Since it has been well established that the various adipose tissue depots demonstrate different responses to stimuli, we assessed the effect of cachexia on some biochemical and morphological parameters of adipocytes obtained from the mesenteric (MES), retroperitoneal (RPAT), and epididymal (EAT) adipose tissues of rats bearing Walker 256 carcinosarcoma, compared with controls. Relative weight and total fat content of tissues did not differ between tumor-bearing rats and controls, but fatty acid composition was modified by cachexia. Adipocyte dimensions were increased in MES and RPAT from tumor-bearing rats, but not in EAT, in relation to control. Ultrastructural alterations were observed in the adipocytes of tumor-bearing rat RPAT (membrane projections) and EAT (nuclear bodies).

show abstract

Anorexia and cancer in animals and man

Cited by 44 publications

References 92 publications

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Suramin interferes with interleukin-6 receptor binding in vitro and inhibits colon-26-mediated experimental cancer cachexia in vivo.

Cancer cachexia

Heterogeneous response of adipose tissue to cancer cachexia

Contact Info

Product

Resources

About